Novel antibody–drug conjugates for triple negative breast cancer

Aiko Nagayama, Neelima Vidula, Leif Ellisen, Aditya Bardia

研究成果: Review article査読

4 被引用数 (Scopus)

抄録

Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody–drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.

本文言語English
ジャーナルTherapeutic Advances in Medical Oncology
12
DOI
出版ステータスPublished - 2020

ASJC Scopus subject areas

  • Oncology

フィンガープリント 「Novel antibody–drug conjugates for triple negative breast cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル